NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free GRI Stock Alerts 0.43 0.00 (-0.05%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range0.42▼0.4650-Day Range0.43▼1.0452-Week Range0.41▼62.23Volume62,200 shsAverage Volume143,770 shsMarket Capitalization$1.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get GRI Bio alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About GRI Bio Stock (NASDAQ:GRI)GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Read More GRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRI Stock News HeadlinesApril 25, 2024 | globenewswire.comGRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarApril 24, 2024 | americanbankingnews.comGRI Bio (NASDAQ:GRI) Stock Price Down 2.8%April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 18, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentApril 16, 2024 | globenewswire.comGRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentApril 8, 2024 | globenewswire.comGRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International ConferenceApril 1, 2024 | globenewswire.comGRI Bio Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comGRI Bio to Present at the MedInvest Biotech & Pharma Investor ConferenceApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 14, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 14, 2024 | finance.yahoo.comGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 14, 2024 | globenewswire.comGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 4, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomMarch 4, 2024 | globenewswire.comGRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomFebruary 23, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)February 3, 2024 | msn.comGRI Bio Launches Major Securities Public OfferingFebruary 2, 2024 | msn.comGRI Bio prices 5M shares at $1.10 in public offeringFebruary 2, 2024 | marketwatch.comGRI Bio Shares Drop After Stock Offering Prices Below Thursday's CloseFebruary 2, 2024 | markets.businessinsider.comGRI Bio Announces Pricing Of $5.5 Mln Public Offering, Stock DownFebruary 2, 2024 | investorplace.comWhy Is GRI Bio (GRI) Stock Down 21% Today?January 26, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Announces Reverse Stock SplitJanuary 26, 2024 | msn.comGRI Bio's board OKs 1-for-7 reverse stock splitJanuary 26, 2024 | finance.yahoo.comGRI Bio Announces Reverse Stock SplitJanuary 9, 2024 | finance.yahoo.comGRI Bio, Inc. (GRI) Stock Historical Prices & Data - Yahoo FinanceJanuary 3, 2024 | chicago.suntimes.comWeed dispensary plan scrapped at old Rainforest Cafe in River NorthDecember 21, 2023 | msn.comGRI Bio files to sell common stock, warrantsNovember 27, 2023 | markets.businessinsider.comGRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%See More Headlines Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRI CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)-81.48 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-795.54% Return on Assets-345.37% Debt Debt-to-Equity RatioN/A Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value0.40 per share Price / Book1.08Miscellaneous Outstanding Shares3,197,000Free Float2,659,000Market Cap$1.37 million OptionableNot Optionable Beta-1.77 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. W. Marc Hertz Ph.D. (Age 53)Co-Founder, CEO, President & Director Comp: $842.01kMs. Leanne M. Kelly (Age 47)CFO & Corporate Secretary Comp: $550.93kDr. Vipin Kumar Chaturvedi Ph.D. (Age 64)Co-Founder & Chief Scientific Officer Dr. Albert Agro Ph.d. (Age 59)Chief Medical Officer Key CompetitorsHistogenNASDAQ:HSTOSunshine BiopharmaNASDAQ:SBFM180 Life SciencesNASDAQ:ATNFNLS PharmaceuticsNASDAQ:NLSPNeuBase TherapeuticsNASDAQ:NBSEView All Competitors GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed in 2024? GRI Bio's stock was trading at 2.70 at the beginning of the year. Since then, GRI stock has decreased by 84.0% and is now trading at 0.43. View the best growth stocks for 2024 here. Are investors shorting GRI Bio? GRI Bio saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 18,300 shares, a drop of 66.2% from the March 31st total of 54,200 shares. Based on an average daily trading volume, of 738,800 shares, the short-interest ratio is presently 0.0 days. Approximately 0.6% of the company's stock are sold short. View GRI Bio's Short Interest. When is GRI Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our GRI earnings forecast. When did GRI Bio's stock split? GRI Bio shares reverse split on the morning of Tuesday, January 30th 2024. The 1-7 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
